. . . . . . . . . "unituxin dinutuximab is indicated in combination with granulocyte macrophage colony stimulating factor gm csf interleukin 2 il 2 and 13 cis retinoic acid ra for the treatment of pediatric patients with high risk neuroblastoma who achieve at least a partial response to prior first line multiagent multimodality therapy see clinical studies 14 unituxin is a gd2 binding monoclonal antibody indicated in combination with granulocyte macrophage colony stimulating factor gm csf interleukin 2 il 2 and 13 cis retinoic acid ra for the treatment of pediatric patients with high risk neuroblastoma who achieve at least a partial response to prior first line multiagent multimodality therapy 1" . . . . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" . "W3bkHC2cpiVGhP++NBsvHvoT2oxPuxwClvXMagZCiSOlsgzJV0o/fgNVSdstjazVxJhMRGD1Cm1DD+rkgdeMhK9q0LjDe2s4JoUTb6JVhII9l84JyBPfXX1z32Lum+oj3xOiDb+n+DzVI3d1TUzo5Iw2tsS5xMyLTrydGFR/2IE=" . . "2021-07-03T14:54:35.900+02:00"^^ . . . . .